2-(2,5-Dioxopyrrolidin-1-yl)-6-[3-(2,5-dioxopyrrol-1-yl)propanoylamino]hexanoate → N-Succinimidyl 6-(3-Maleimidopropionamido) Hexanoate

HRID 338044Notes

Reaction equation

HRID 338044 reaction equation
C1(=O)N([CH:6]([CH2:10][CH2:11][CH2:12][CH2:13][NH:14][C:15](=[O:25])[CH2:16][CH2:17][N:18]2[C:22](=[O:23])[CH:21]=[CH:20][C:19]2=[O:24])[C:7]([O-:9])=[O:8])C(=O)CC1>OP([O-])(O)=O.OP([O-])([O-])=O.[Na+].[Na+].[Na+].[Cl-].[Cl-].[K+].[K+].CS(C)=O>[CH2:21]1[C:22](=[O:23])[N:18]([O:9][C:7]([CH2:6][CH2:10][CH2:11][CH2:12][CH2:13][NH:14][C:15]([CH2:16][CH2:17][N:18]2[C:19](=[O:24])[CH:20]=[CH:21][C:22]2=[O:23])=[O:25])=[O:8])[C:19](=[O:24])[CH2:20]1

Participants

4

Reactant 1

HCID 1317320532-(2,5-Dioxopyrrolidin-1-yl)-6-[3-(2,5-dioxopyrrol-1-yl)propanoylamino]hexanoate4×

Product 1

HCID 4170355N-Succinimidyl 6-(3-Maleimidopropionamido) Hexanoate

Reagents, catalysts & solvents 2

HCID 679Dimethyl SulfoxideSolvent2×HCID 24978514Phosphate Buffered SalineSolvent2×

Procedure

To a sample bottle (8 mL volume), it was charged by 0.39 mL of human CO hemoglobin (Hb) solution (509 μM), and diluted with 1.61 mL of phosphate buffered saline solution (PBS) to be 0.1 mM 2 mL. Next, 7.6 mg of succinimidyl-6-(β-maleimidopropionamido)hexanoate (SMPH, manufactured by Pierce Corporation) was dissolved in 0.25 mL of dimethyl sulfoxide (DMSO) to prepare 80 mM dimethyl sulfoxide (DMSO) solution of succinimidyl-6-(β-maleimidopropionamido)hexanoate (SMPH). To the above human hemoglobin (Hb) solution (2 mL), it was added with 0.047 mL of succinimidyl-6-(β-maleimidopropionamido)hexanoate (SMPH) solution (succinimidyl-6-(β-maleimidopropionamido)hexanoate/human hemoglobin (SMPH/Hb) =18 (mol/mol)), while stirring (100 rpm), and stirred at room temperature for 30 minutes. From the resultant reaction solution, unreacted succinimidyl-6-(β-maleimidopropionamido)hexanoate (SMPH) was removed by the same method as the method described in Preparation Example 2 in Example 1. Specifically, 2.1 mL of human hemoglobin (Hb) solution was moved to a centrifugal concentrator (Vivaspin 20), diluted with about 18 mL of phosphate buffered saline solution (PBS) to ten times, and then concentrated to about 1.0 mL ( 1/10) at 4000 rpm, for 30 minutes and at 4° C. To that, it was added with 19 mL of phosphate buffered saline solution (PBS), and concentrated to about 1.0 mL under the same conditions. By repeating this dilution/concentration operation three times, unreacted succinimidyl-6-(β-maleimidopropionamido)hexanoate (SMPH) was removed. Lastly, a sample in a tube was moved to a sample bottle (8 mL volume), and the total volume was adjusted with phosphate buffered saline solution (PBS) to 2.0 mL. The human hemoglobin-crosslinker conjugate (Hb-SMPH) concentration became 0.1 mM.

Workup

  1. stirringstirred at room temperature for 30 minutes
  2. customwas removed by the same method as the method
  3. customdescribed in Preparation Example 2 in Example 1
  4. concentrationconcentrated to about 1.0 mL ( 1/10) at 4000 rpm, for 30 minutes and at 4° C
  5. additionTo that, it was added with 19 mL of phosphate buffered saline solution (PBS)
  6. concentrationconcentrated to about 1.0 mL under the same conditions
  7. customwas removed
  8. customLastly, a sample in a tube was moved to a sample bottle (8 mL volume)
  9. concentrationThe human hemoglobin-crosslinker conjugate (Hb-SMPH) concentration

Sources & evidence

ORD record
ord-97a185b8364d478d9279c41f32a995c0
Source dataset
uspto-grants-2014_11
Patent number
US08889830B2

Reaction notes

Loading…